News for Athersys Inc (4LS.BE)

Published at

Feb 15, 2021 6:00 PM

by prnewswire.com

mixed

mixed

Global Mesenchymal Stem Cells (MSC) Market Report 2021-2027: Market Competitors areExploring Commercialization Strategies for MSC-Derived Extracellular Vesicles (EVs) and Exosomes

/PRNewswire/ -- The

CYYNF CYP.AX AVCO ATHX 7774.T 51S.HM 51S.F 4LS.MU 4LS.F 4LS.BE 166480.KQ RGS.AX PSTI.TA PSTI PJT.F PJT.BE OM2.F OFIX EJU.MU EJU.F EJU.BE AGE AEMD 065660.KQ 005690.KS OCC.AX NUVA NK8.F 5FA.F

Read more →
Published at

Feb 15, 2021 6:00 PM

by thestreet.com

mixed

mixed

Global Mesenchymal Stem Cells (MSC) Market Report 2021-2027: Market Competitors AreExploring Commercialization Strategies For MSC-Derived Extracellular Vesicles (EVs) And Exosomes

DUBLIN, Feb. 15, 2021 /PRNewswire/ -- The

CYYNF CYP.AX AVCO ATHX 7774.T 51S.HM 51S.F 4LS.MU 4LS.F 4LS.BE 166480.KQ RGS.AX PSTI.TA PSTI PJT.F PJT.BE OM2.F OFIX EJU.MU EJU.F EJU.BE AGE AEMD 065660.KQ 005690.KS OCC.AX NUVA NK8.F 5FA.F

Read more →
Published at

Feb 1, 2021 1:25 AM

by seekingalpha.com

positive

positive

Athersys: Risky Financial Position, But Promising Upside By FYE 2023 (NASDAQ:ATHX)

Athersys, Inc. is a late-stage international biotechnology company focused on regenerative medicine, primarily stem cell therapy.

ATHX 4LS.MU 4LS.F 4LS.BE

Read more →